Homocysteine—a novel risk factor for vascular disease

Grundy SM , Pasternak R , Greenland P , Smith S Jr Fuster V. AHA/ACC scientific statement. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999; 34: 1348–59

van den Hoogen PC , Feskens EJ , Nagelkerke NJ , Menotti A , Nissinen A , Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000; 342: 1–8

Anand SS , Yusuf S , Vuksan V Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000; 356: 279–84

Scott JM , Weir DG. Folic acid, homocysteine and one-carbon metabolism: a review of the essential biochemistry. J Cardiovasc Risk 1998; 5: 223–7

Ueland PM. Homocysteine species as components of plasma redox thiol status. Clin Chem 1995; 41: 340–2

Fiskerstrand T , Refsum H , Kvalheim G , Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 1993; 39: 263–71

Pfeiffer CM , Twite D , Shih J , Holets M Sr , Gunter EW. Method comparison for total plasma homocysteine between the Abott IMx analyzer and an HPLC assay with internal standardization. Clin Chem 1999; 45: 152–3

Mayer EL , Jacobsen DW , Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517–27

Frosst P , Blom HJ , Milos R A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111–13

Brattstrom L , Wilcken DE , Ohrvik J , Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98: 2520–6

Guttormsen AB , Schneede J , Fiskerstrand T , Ueland PM , Refsum HM. Plasma concentrations of homocysteine and other aminothiol compounds are related to food intake in healthy human subjects. J Nutr 1994; 124: 1934–41

Selhub J , Jacques PF , Wilson PW , Rush D , Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693–8

Gupta A , Moustapha A , Jacobsen DW High homocysteine, low folate, and low vitamin B6 concentrations: prevalent risk factors for vascular disease in heart transplant recipients. Transplantation 1998; 65: 544–50

Bostom AG , Gohh RY , Tsai MY Excess prevalence of fasting and postmethionine-loading hyperhomocysteinemia in stable renal transplant recipients. Arterioscler Thromb Vasc Biol 1997; 17: 1894–900

McCully KS. Vascular pathology of homocyst(e)inemia: implications for the development of arteriosclerosis. Am J Pathol 1969; 56: 111–28

Mudd SH , Skovby F , Levy HL , Pettigrew KR , Wilcken B , Pyeritz R. The natural history of homocystinuria due to cystathionine b-synthase deficiency. Am J Hum Genet 1985; 37: 1–31

Wilcken DE , Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 1997; 20: 295–300

Boushey CJ , Beresford SA , Omenn GS , Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049–57

Danesh J , Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998; 5: 229–32

Graham IM , Daly LE , Refsum HM Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775–81

Nygard O , Nordrehaug JE , Refsum H , Ueland PM , Farstad M , Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230–6

Alfthan G , Aro A , Gey KF. Plasma homocysteine and cardiovascular disease mortality. Lancet 1997; 349: 397

Chambers JC , Obeid OA , Refsum H Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet 2000; 355: 523–7

Chambers JC , Ireland H , Thompson E The methylenetetra-hydrofolate reductase 677 C → T mutation, and coronary heart disease risk in UK Indian Asians. Arterioscler Thromb Vasc Biol (in press)

Ubbink JB , Delport R , Vermaak WJ. Plasma homocysteine concentrations in a population with a low coronary heart disease prevalence. J Nutr 1996; 126: 1254S–7S

Dudman NP. An alternative view of homocysteine. Lancet 1999; 354: 2072–4

Chambers JC , McGregor A , Jean Marie J , Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1997; 351: 36–7

Chambers JC , McGregor A , Jean Marie J , Obeid OA , Kooner JS. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 1999; 99: 1156–60

Chambers JC , Obeid OA , Kooner JS. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Artenosclet Thromb Vasc Biol 1999; 19: 2922–7

Bellamy MF , McDowell IF , Ramsey MW Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998; 98: 1848–52

Kanani PM , Sinkey CA , Browning RL , Allaman M , Knapp HR , Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation 1999; 100: 1161–8

Stamler JS , Osborne JA , Jaraki O Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308–18

Blundell G , Jones BG , Rose FA , Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996; 122: 163–72

Dudman NP , Temple SE , Guo XW , Fu W , Perry MA. Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats in vivo. Circ Res 1999; 84: 409–16

Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5–7

Kojda G , Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43: 562–71

Ventura P , Panini R , Verlato C , Scarpetta G , Salvioli G. Peroxidation indices and total antioxidant capacity in plasma during hyperhomocysteinemia induced by methionine oral loading. Metabolism 2000; 49: 225–8

Voutilainen S , Morrow JD , Roberts LJ Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels. Arterioscler Thromb Vasc Biol 1999; 19: 1263–6

Jakubowski H , Zhang L , Bardeguez A , Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res 2000; 87: 45–51

Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999; 13: 2277–83

Homocysteine Lowering Trialists’ Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316: 894–8

Clarke R , Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998; 5: 249–55

Woo KS , Chook P , Lolin YI , Sanderson JE , Metreweli C , Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999; 34: 2002–6

Bellamy MF , McDowell IF , Ramsey MW , Brownlee M , Newcombe RG , Lewis MJ. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest 1999; 29: 659–62

van den BM , Boers GH , Franken DG Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176–81

Chambers JC , Ueland PM , Obeid OA , Wrigley J , Refsum H , Kooner JS. Improved vascular endothelial function after oral B vitamins; an effect mediated through reduced concentrations of free plasma homocysteine. Circulation (in press)

Vermeulen EG , Stehouwer CD , Twisk JW Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000; 355: 517–22

Nappo F , De Rosa N , Marfella R Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281: 2113–18

Lentz SR , Sobey CG , Piegors DJ Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia J Clin Invest 1996; 98: 24–9